Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

CAR T Cell Functionality Correlates With Outcomes, Offering a Biomarker for Response

April 4th 2017

The flexibility of CAR T cells to perform multiple functions was associated with the level of clinical activity elicited for patients with advanced non-Hodgkin’s lymphoma, according to a retrospective analysis presented at the 2017 AACR Annual Meeting.

Function of IDH Mutations Can Be Exploited by PARP Inhibitors Instead of IDH Inhibitors

April 4th 2017

A phase II basket trial has been announced to test that mutations in isocitrate dehydrogenase 1 and 2 are not driver mutations that should be targeted with direct IDH inhibitors, but instead they create vulnerabilities that can be exploited through treatment with PARP inhibitors.

CAR T-Cell Response Rate Tops 80% in NHL Trial

April 4th 2017

Results of a phase II trial showed that more than 80% of patients with refractory non-Hodgkin lymphoma achieved objective responses to treatment with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel.

Dr. Neelapu on Primary Results of the ZUMA-1 Trial in NHL

April 2nd 2017

Sattva S. Neelapu, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses primary results of the ZUMA-1 trial investigating axicabtagene ciloleucel (KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma.

FDA Submission Completed for Axicabtagene Ciloleucel in NHL

April 1st 2017

A biologics license application has been submitted for axicabtagene ciloleucel as a potential treatment for transplant ineligible patients with relapsed or refractory aggressive non-Hodgkin lymphoma.

Dr. Wei on Trial of Venetoclax Plus Chemotherapy in AML

March 30th 2017

Andrew Wei, MBBS, PhD, clinical hematologist, head of Leukemia Research Group, Alfred Hospital, discusses venetoclax (Venclexta) plus chemotherapy in advanced myeloid leukemia (AML).

FDA Grants Priority Review to sBLA for Full Approval of Blinatumomab in ALL

March 30th 2017

The FDA has granted a priority review to a supplemental biologics license application supporting the conversion of the accelerated approval of blinatumomab to a full approval as a treatment for patients with Philadelphia chromosome-negative relapsed/refractory B-precursor acute lymphoblastic leukemia.

FDA Grants Priority Review to CTL019 for ALL

March 30th 2017

The FDA has granted a priority review designation to tisagenlecleucel-T as a treamtnet for pediatric and young adult patients with relapsed and refractory B-cell acute lymphoblastic leukemia, making it the first CAR T-cell therapy to enter regulatory review.

Dr. Fanale on Challenges Facing Treatments in T-Cell Lymphoma

March 30th 2017

Michelle A. Fanale, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses challenges with treatment options for patients with T-cell lymphoma.

FDA Panel Supports Subcutaneous Rituximab for Blood Cancers

March 29th 2017

The FDA's Oncologic Drugs Advisory Committee unanimously (11-0) recommended approval of subcutaneous rituximab for the treatment of patients with certain blood cancers.

FDA Warning Links Breast Implants to ALCL

March 29th 2017

Breast implants may increase an individual’s risk of developing anaplastic large cell lymphoma, a recent FDA advisory warned.

MCL Landscape Shifting With Combo Regimens on Horizon

March 27th 2017

Andre Goy, MD, highlights what researchers can expect next in the field of mantle cell lymphoma, given recent pivotal data from clinical trials.

Pembrolizumab Recommended for EU Approval in Hodgkin Lymphoma

March 25th 2017

The EMA’s Committee for Medicinal Products for Human Use has recommended approval of pembrolizumab for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma who have progressed following autologous stem cell transplant and brentuximab vedotin, or who are transplant-ineligible and have failed brentuximab vedotin.

Dr. Garfall on Impact of CAR T-Cell Therapy in Hematologic Malignancies

March 22nd 2017

Alfred L. Garfall, MD, MS, assistant professor of Medicine, the Hospital of the University of Pennsylvania, discusses the impact of chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies.

Expert Discusses Success of Blinatumomab in ALL

March 21st 2017

Hagop Kantarjian, MD, discusses the success of blinatumomab and next steps with the anti-CD19 agent.

Expert Discusses Promise of Quizartinib in AML

March 15th 2017

Mark Levis, MD, PhD, highlights the promise and potential challenges of the FLT3-inhibitor quizartinib in acute myeloid leukemia.

Dr. Straus on FDA Approval of Pembrolizumab in Hodgkin Lymphoma

March 15th 2017

David J. Straus, MD, internist and hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of pembrolizumab (Keytruda) as a treatment for patients with Hodgkin lymphoma.

FDA Approves Pembrolizumab for Hodgkin Lymphoma

March 15th 2017

The FDA has granted an accelerated approval to pembrolizumab (Keytruda) for the treatment of adult and pediatric patients with classical Hodgkin lymphoma (cHL) who are refractory or have relapsed after 3 or more lines of therapy.

FDA Places Partial Clinical Hold on Selinexor Trials

March 14th 2017

The FDA has placed a partial clinical hold on trials of selinexor (KPT-330), which is being explored in several tumor types.

Imatinib Continues to Impress in Long-Term CML Analysis

March 10th 2017

Imatinib continued to show dramatic overall survival benefits after nearly 11 years of follow-up despite crossover for patients with Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase.